Latest Articles
‘I convinced my family to go on the Human Being Diet. We lost 10st between us’ - The Telegraph
‘I convinced my family to go on the Human Being Diet. We lost 10st between us’ The Telegraph
Published: June 20, 2025, 9 a.m.
The disease course in microscopic colitis may be influenced by hormonal factors - BMC Gastroenterology
The disease course in microscopic colitis may be influenced by hormonal factors BMC Gastroenterology
Published: June 19, 2025, 4:25 p.m.
Who is Mona Ghosh? This Indian-origin OB-GYN sentenced to 10 years for $2.4 million fraud scheme - financialexpress.com
Who is Mona Ghosh? This Indian-origin OB-GYN sentenced to 10 years for $2.4 million fraud scheme financialexpress.com
Published: June 13, 2025, 4:28 p.m.
Women's Health Therapeutics Market Revenue to Attain USD 64.04 Bn by 2033 - Precedence Research
Women's Health Therapeutics Market Revenue to Attain USD 64.04 Bn by 2033 Precedence Research
Published: June 13, 2025, 1:43 p.m.
From challenges to solutions: The promise of regenerative medicine and tissue engineering in restoring female reproductive health - ScienceDirect.com
From challenges to solutions: The promise of regenerative medicine and tissue engineering in restoring female reproductive health ScienceDirect.com
Published: June 13, 2025, 12:31 p.m.
Stress-Induced Hyperprolactinemia Mimicking Pituitary Pathology: A Diagnostic Challenge - Cureus
Stress-Induced Hyperprolactinemia Mimicking Pituitary Pathology: A Diagnostic Challenge Cureus
Published: June 12, 2025, 7:33 a.m.
Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer - Physician's Weekly
Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer Physician's Weekly
Published: June 10, 2025, 6:31 a.m.
Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer - HealthDay
Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer HealthDay
Published: June 9, 2025, 2:50 p.m.
AZN Initiates Phase 3 Trial for Enhertu in Advanced Endometrial Cancer | AZN Stock News - GuruFocus
AZN Initiates Phase 3 Trial for Enhertu in Advanced Endometrial Cancer | AZN Stock News GuruFocus
Published: June 9, 2025, 12:46 p.m.
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - BioSpace
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer BioSpace
Published: June 9, 2025, 12:43 p.m.
Link copied to clipboard!